Unbound MEDLINE

Does the dexamethasone suppression test reliably discriminate between psychotic and nonpsychotic major depression?: an exploratory analysis of potential confounds. The Journal of nervous and mental disease [J Nerv Ment Dis] Journal article

 
TitleDoes the dexamethasone suppression test reliably discriminate between psychotic and nonpsychotic major depression?: an exploratory analysis of potential confounds.
Author(s)Gaudiano BA, Epstein-Lubow G, Miller IW 
InstitutionDepartment of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. Brandon_Gaudiano@brown.edu
SourceJ Nerv Ment Dis 2009 Jun; 197(6):395-400.
MeSHAdrenal Cortex Hormones
Adrenocorticotropic Hormone
Adult
Antipsychotic Agents
Anxiety Disorders
Biological Markers
Depressive Disorder, Major
Dexamethasone
Diagnosis, Differential
Diagnostic and Statistical Manual of Mental Disorders
Female
Hospitalization
Humans
Hydrocortisone
Hypothalamo-Hypophyseal System
Male
Pituitary-Adrenal System
Psychotherapy
Psychotic Disorders
Questionnaires
Severity of Illness Index
AbstractPrevious research has shown that psychotic major depression (PMD) is often associated with higher rates of nonsuppression on the dexamethasone suppression test (DST) compared with nonpsychotic major depression (NMD), suggesting the potential importance of cortisol hypersecretion in the psychotic subtype of the disorder. However, these patient groups also are known to differ from one another on a variety of other clinical variables, and there are numerous factors independent of diagnostic status known to affect the DST. Thus, we investigated possible confounds that could help account for the apparent DST abnormalities in PMD sometimes reported in past research. Hospitalized patients with PMD (n = 11) and NMD (n = 58) were compared on the DST and other clinical variables. As expected, PMD patients showed significantly higher rates of DST nonsuppression (55% vs. 24%; p = 0.04). However, PMD patients also had significantly higher levels of anxiety severity (p = 0.01). The higher rates of nonsuppression in the PMD group were attenuated when these patients were compared with a subsample of NMD patients matched on anxiety severity (55% vs. 55%). Implications for future research on biological markers of PMD are discussed.
Languageeng
Pub Type(s)Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
PubMed ID19525738
  
Advertise on this site.